Glycopyrroniumbromid Accord (Glycopyrronium Bromide)

Glycopyrroniumbromid Accord is indicated for several clinical situations where reduction of secretions or bronchodilation is required.

• Prevention of excessive salivation during surgical procedures, especially in oral and maxillofacial operations.
• Maintenance bronchodilator therapy in chronic obstructive pulmonary disease (COPD), helping to improve airflow and reduce exacerbations.
• Acute management of bronchospasm in patients with COPD or asthma, administered when rapid airway opening is needed.
• Adjunctive treatment to facilitate endotracheal intubation by decreasing oral and airway secretions, thereby improving visualization for the clinician.
• Use as an antisecretory agent in patients with hypersecretory conditions such as peptic ulcer disease or gastrointestinal bleeding, to limit fluid loss.

The safety profile of Glycopyrroniumbromid Accord includes a range of observed adverse effects, which are generally categorized by frequency.

Common

• Dry mouth (xerostomia), a reduction in salivary flow that may cause throat discomfort.
• Mild facial flushing, usually transient and without itching.
• Transient increase in heart rate (tachycardia), often asymptomatic.
• Nausea or mild gastrointestinal discomfort, typically short‑lived.
• Blurred vision, occasionally reported during rapid infusion.
• Constipation, presenting as infrequent bowel movements.

Serious

• Severe bronchospasm or paradoxical bronchoconstriction, which may worsen breathing difficulty.
• Allergic reactions such as rash, urticaria, or anaphylaxis, requiring immediate medical attention.
• Cardiac arrhythmias, including irregular heart rhythms that could be life‑threatening.
• Acute urinary retention, a sudden inability to void that may need catheterization.

When prescribing Glycopyrroniumbromid Accord, clinicians should consider several precautionary measures to ensure safe use.

• Assess cardiovascular status because tachycardia or arrhythmias may occur.
• Use caution in patients with glaucoma, urinary retention, or other anticholinergic‑sensitive conditions.
• Evaluate renal and hepatic function before initiating therapy.
• Avoid use during pregnancy or lactation unless benefits clearly outweigh unknown risks.
• Monitor for allergic reactions and adjust dose in elderly patients.
• Review concomitant medications for anticholinergic load to prevent additive effects.
• Ensure proper dilution and administration rate to minimize local irritation.

Glycopyrroniumbromid Accord can interact with other medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with other anticholinergic agents (e.g., atropine, scopolamine) due to additive anticholinergic effects.
• Combination with beta‑adrenergic antagonists may blunt bronchodilatory response.

Use with caution

• Concurrent use with cholinesterase inhibitors (e.g., pyridostigmine) may reduce therapeutic effect.
• Co‑administration with drugs that prolong QT interval (e.g., certain antiarrhythmics) requires ECG monitoring.
• Use cautiously with anesthetic agents that depress respiration, especially during surgery.
• Use with caution when combined with antihistamines that have anticholinergic properties, as they may increase dry mouth and urinary retention.